Retatrutide
Retatrutide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Retatrutide is described in the retrieved literature as a GIP, GLP-1 and glucagon receptor agonist, that is a triple hormone receptor agonist. The retrieved record set is smaller and more recent than for the older members of this class: a 2023 New England Journal of Medicine phase 2 trial report in obesity and a 2023 Lancet randomised trial report in people with type 2 diabetes.
Later retrieved reports cover a 2024 Nature Medicine trial in metabolic dysfunction-associated steatotic liver disease, a 2025 Lancet Diabetes and Endocrinology body-composition substudy, and a 2024 European Journal of Clinical Pharmacology review of the compound as an investigational agent. No PubChem compound record was returned for this name, so its identity fields are recorded as not sourced rather than estimated.
[2, 3, 4, 5, 6]Reported mechanism
Triple agonist at the GIP, glucagon-like peptide-1 and glucagon receptors.
[3]Stated in the title of the cited 2023 Lancet trial report.
Targets named in the cited records: GIP receptor, GLP-1 receptor, glucagon receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Retatrutide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- LY3437943
Where this page sits
Research records
Cited research records for Retatrutide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Retatrutide
Compounds indexed next to it
- Tirzepatide — Incretin receptor agonists
- Semaglutide — Incretin receptor agonists
- Liraglutide — Incretin receptor agonists
- Maridebart cafraglutide — Incretin receptor agonists
- Survodutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Retatrutide?
Retatrutide is described in the retrieved literature as a GIP, GLP-1 and glucagon receptor agonist, that is a triple hormone receptor agonist. The retrieved record set is smaller and more recent than for the older members of this class: a 2023 New England Journal of Medicine phase 2 trial report in obesity and a 2023 Lancet randomised trial report in people with type 2 diabetes.
Which class is Retatrutide indexed under?
Retatrutide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Retatrutide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:retatrutide
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med (2023). pmid:37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med (2024). pmid:38858523
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol (2025). pmid:40609566
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol (2024). pmid:38367045
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.